High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
Market Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q2
FY2025Q3
FY2025Q4
--
--
-0.390
+25.81%
--
--
-0.393
+40.18%
--
--
-0.050
-84.38%
Estimates Revision
The market is revising No Change the revenue expectations for Belite Bio, Inc (BLTE) for FY2025, with the revenue forecasts being adjusted by 0% over the past three months. During the same period, the stock price has changed by 9.54%.
Revenue Estimates for FY2025
No Change
0.00%
In Past 3 Month
EPS Estimates for FY2025
Revise Upward
+53.66%
In Past 3 Month
Stock Price
Go Up
+9.54%
In Past 3 Month
5 Analyst Rating
0Wall Street analysts forecast BLTE stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for BLTE is 96.67 USD with a low forecast of 80.00 USD and a high forecast of 110.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
5 Buy
0 Hold
0 Sell
Strong Buy
0Current: 59.260
Low
80.00
Averages
96.67
High
110.00
0Current: 59.260
Low
80.00
Averages
96.67
High
110.00
Benchmark
Bruce Jackson
Strong Buy
Reiterates
$80
2025-03-26
Reason
Benchmark
Bruce Jackson
Price Target
$80
2025-03-26
Reiterates
Strong Buy
Reason
Benchmark raised the firm's price target on Belite Bio to $80 from $79 and keeps a Buy rating on the shares. In February, Belite received a positive report from an interim data analysis of the Phase 3 DRAGON trial and a DSMB recommendation to seek accelerated regulatory approval, notes the analyst, who calls out completion of the DRAGON II study around mid-year and completion of the DRAGON study by year-end 2025 as the next major catalysts for the shares.
HC Wainwright & Co.
Yi Chen
Strong Buy
Reiterates
$100
2025-03-18
Reason
HC Wainwright & Co.
Yi Chen
Price Target
$100
2025-03-18
Reiterates
Strong Buy
Reason
Cantor Fitzgerald
Jennifer Kim
Buy
Reiterates
n/a
2025-03-18
Reason
Cantor Fitzgerald
Jennifer Kim
Price Target
n/a
2025-03-18
Reiterates
Buy
Reason
Benchmark
Bruce Jackson
Strong Buy
Maintains
$57 → $79
2025-01-21
Reason
Benchmark
Bruce Jackson
Price Target
$57 → $79
2025-01-21
Maintains
Strong Buy
Reason
Benchmark raised the firm's price target on Belite Bio to $79 from $57 and keeps a Buy rating on the shares. After speaking to management at a conference last week, the firm revisited its pricing assumptions for Tinlarebant in the treatment of Stargardt disease type 1 and now assumes an average price of $50,000, the analyst tells investors.
Maxim Group
Jason McCarthy
Strong Buy
Maintains
$60 → $110
2024-11-15
Reason
Maxim Group
Jason McCarthy
Price Target
$60 → $110
2024-11-15
Maintains
Strong Buy
Reason
HC Wainwright & Co.
Yi Chen
Strong Buy
Maintains
$60 → $100
2024-11-13
Reason
HC Wainwright & Co.
Yi Chen
Price Target
$60 → $100
2024-11-13
Maintains
Strong Buy
Reason
See All Ratings
Valuation Metrics
The current forward P/E ratio for Belite Bio Inc (BLTE.O) is -44.96, compared to its 5-year average forward P/E of -34.49. For a more detailed relative valuation and DCF analysis to assess Belite Bio Inc 's fair value, click here.
Forward PE
The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
N/A
5Y Average PE
-34.49
Current PE
-44.96
Overvalued PE
-24.01
Undervalued PE
-44.96
Forward EV/EBITDA
The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
N/A
5Y Average EV/EBITDA
0.00
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
0.00
Undervalued EV/EBITDA
0.00
Forward PS
The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
N/A
5Y Average PS
13.72
Current PS
193.53
Overvalued PS
63.87
Undervalued PS
-36.42
Financials
Annual
Quarterly
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
Trading Trends
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
BLTE News & Events
Events Timeline
(ET)
2025-07-02
05:11:57
Belite Bio completes enrollment in PHOENIX trial
2025-05-21 (ET)
2025-05-21
05:23:41
Belite Bio announces Breakthrough Therapy Designation for Tinlarebant from FDA
2025-05-14 (ET)
2025-05-14
05:24:39
Belite Bio reports Q1 EPS (27c), consensus (37c)
Sign Up For More Events
Sign Up For More Events
News
Preview
4.0
07-03BenzingaHC Wainwright & Co. Reiterates Buy on Belite Bio, Maintains $100 Price Target
Preview
9.0
07-02NewsfilterBelite Bio Announces Completion of Enrollment in the Pivotal Global Phase 3 PHOENIX Trial Evaluating Oral Tinlarebant in Geographic Atrophy
Preview
2.0
06-07NASDAQ.COMBLTE Crosses Below Key Moving Average Level
Sign Up For More News
People Also Watch
FAQ
What is Belite Bio Inc (BLTE) stock price today?
What is Belite Bio Inc (BLTE)'s business?
What is the price predicton of BLTE Stock?
What is Belite Bio Inc (BLTE)'s revenue for the last quarter?
What is Belite Bio Inc (BLTE)'s earnings per share (EPS) for the last quarter?
What changes have occurred in the market's expectations for Belite Bio Inc (BLTE)'s fundamentals?
How many employees does Belite Bio Inc (BLTE). have?